Online health platform Noom recently launched its Noom Microdose GLP-1 Rx Program to reportedly address barriers to GLP-1s, including medication cost
These effects typically emerge during dose escalation and often diminish over time as the body adapts to treatment
A systematic review and meta-analysis published in Diabetes, Obesity and Metabolism examined cardiovascular outcome trials involving over 60,000 patients treated with GLP-1 receptor agonists
The drugs were linked to small reduction 12% in the risk of dementia and other neurocognitive disorders, including Alzheimers disease
QuickMD has strict referencing policies and relies on reputable sources, including peer-reviewed research, clinical guidelines, medical organizations, and government and public health agencies, among others
Potential downsides include a slower onset of significant weight loss compared to tirzepatide and gastrointestinal side effects, particularly nausea during the first month, that can be challenging when you are already dealing with fatigue and disrupted eating patterns
